文献速递心脑血管急症重症综合管理与镇静镇痛

美国Ad26.COV2.S疫苗接种后伴血小板减少的脑静脉窦血栓病例报告,2021年3月2日至4月21日

US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021.
PubMed 文献 · JAMA · 2021-01-01
一句话结论Ad26.COV2.S疫苗接种后6-15天出现头痛伴血小板减少者,需警惕脑静脉窦血栓,本组12例中7例合并脑出血、3例死亡。

该研究描述了2021年3月2日至4月21日向美国疫苗不良事件报告系统(VAERS)报告的12例接种Ad26.COV2.S疫苗后发生伴血小板减少的脑静脉窦血栓(CVST)病例。患者均为白人女性,年龄18岁至不足60岁,来自11个州,症状出现时间为接种后6至15天,11例以头痛起病。12例中7例合并脑出血,8例合并非CVST血栓,11例接受肝素-血小板因子4 HIT抗体ELISA筛查者全部阳性。截至2021年4月21日,3例死亡、3例继续ICU治疗、2例继续非ICU住院、4例出院回家。作者认为这些病例代表严重事件,可能为临床指导和疫苗与CVST伴血小板减少潜在关系的调查提供信息。

要点

  • 接种Ad26.COV2.S疫苗后6至15天出现头痛,需警惕CVST伴血小板减少,本组11例以头痛起病。
  • 12例CVST伴血小板减少患者中7例合并脑出血、8例合并非CVST血栓,病情严重。
  • 11例接受肝素-血小板因子4 HIT抗体ELISA筛查者全部阳性,提示类HIT机制。
  • 血小板最低值范围为9×10³/µL至127×10³/µL,6例在诊断CVST后初始接受肝素治疗。
  • 截至2021年4月21日,3例死亡、3例继续ICU治疗、2例继续非ICU住院、4例出院回家。

适用人群与场景

  • 2021年3月2日至4月21日向VAERS报告的12例接种Ad26.COV2.S疫苗后发生CVST伴血小板减少的美国患者,年龄18岁至不足60岁,均为白人女性,来自11个州。
  • 7例患者至少有1项CVST危险因素:肥胖(n=6)、甲状腺功能减退(n=1)、口服避孕药使用(n=1);无患者有既往肝素暴露记录。

处置流程与药物剂量

  • 诊断CVST后,6例患者初始接受肝素治疗。

红旗征与不能漏的情况

  • 接种Ad26.COV2.S疫苗后6至15天出现头痛(11例以头痛起病,1例以背痛起病后出现头痛),需警惕CVST伴血小板减少。
  • 12例CVST患者中7例合并脑出血、8例合并非CVST血栓,提示病情危重。
  • 血小板最低值范围为9×10³/µL至127×10³/µL,血小板减少提示需评估HIT样机制。

研究设计与关键结果

  • 病例系列研究,纳入12例接种Ad26.COV2.S疫苗后发生CVST伴血小板减少的美国患者,报告来源为VAERS、病历回顾和与临床医生讨论。
  • 患者年龄18岁至不足60岁,均为白人女性,来自11个州;7例有至少1项CVST危险因素(肥胖n=6、甲状腺功能减退n=1、口服避孕药使用n=1),无既往肝素暴露记录。
  • 从接种Ad26.COV2.S疫苗到症状出现的时间为6至15天;11例初始表现为头痛,1例初始表现为背痛后出现头痛。
  • 12例CVST患者中7例合并脑出血,8例合并非CVST血栓;诊断CVST后6例初始接受肝素治疗。
  • 血小板最低值范围为9×10³/µL至127×10³/µL;11例接受肝素-血小板因子4 HIT抗体ELISA筛查者全部阳性。
  • 所有患者均住院(10例在ICU);截至2021年4月21日,结局为死亡(n=3)、继续ICU治疗(n=3)、继续非ICU住院(n=2)、出院回家(n=4)。

证据类型、等级与局限

  • 证据类型:病例系列(12例),来自VAERS报告、病历回顾和与临床医生讨论。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,这初始12例美国Ad26.COV2.S疫苗接种后CVST伴血小板减少病例代表严重事件,可能为Ad26.COV2.S疫苗接种在美国恢复时的临床指导以及调查Ad26.COV2.S疫苗与CVST伴血小板减少之间潜在关系提供信息。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Cerebral venous sinus thrombosis (CVST) with thrombocytopenia, a rare and serious condition, has been described in Europe following receipt of the ChAdOx1 nCoV-19 vaccine (Oxford/AstraZeneca), which uses a chimpanzee adenoviral vector. A mechanism similar to autoimmune heparin-induced thrombocytopenia (HIT) has been proposed. In the US, the Ad26.COV2.S COVID-19 vaccine (Janssen/Johnson & Johnson), which uses a human adenoviral vector, received Emergency Use Authorization (EUA) on February 27, 2021. By April 12, 2021, approximately 7 million Ad26.COV2.S vaccine doses had been given in the US, and 6 cases of CVST with thrombocytopenia had been identified among the recipients, resulting in a temporary national pause in vaccination with this product on April 13, 2021.

OBJECTIVE: To describe reports of CVST with thrombocytopenia following Ad26.COV2.S vaccine receipt.

DESIGN, SETTING, AND PARTICIPANTS: Case series of 12 US patients with CVST and thrombocytopenia following use of Ad26.COV2.S vaccine under EUA reported to the Vaccine Adverse Event Reporting System (VAERS) from March 2 to April 21, 2021 (with follow-up reported through April 21, 2021).

EXPOSURES: Receipt of Ad26.COV2.S vaccine.

MAIN OUTCOMES AND MEASURES: Clinical course, imaging, laboratory tests, and outcomes after CVST diagnosis obtained from VAERS reports, medical record review, and discussion with clinicians.

RESULTS: Patients' ages ranged from 18 to younger than 60 years; all were White women, reported from 11 states. Seven patients had at least 1 CVST risk factor, including obesity (n = 6), hypothyroidism (n = 1), and oral contraceptive use (n = 1); none had documented prior heparin exposure. Time from Ad26.COV2.S vaccination to symptom onset ranged from 6 to 15 days. Eleven patients initially presented with headache; 1 patient initially presented with back pain and later developed headache. Of the 12 patients with CVST, 7 also had intracerebral hemorrhage; 8 had non-CVST thromboses. After diagnosis of CVST, 6 patients initially received heparin treatment. Platelet nadir ranged from 9 ×103/µL to 127 ×103/µL. All 11 patients tested for the heparin-platelet factor 4 HIT antibody by enzyme-linked immunosorbent assay (ELISA) screening had positive results. All patients were hospitalized (10 in an intensive care unit [ICU]). As of April 21, 2021, outcomes were death (n = 3), continued ICU care (n = 3), continued non-ICU hospitalization (n = 2), and discharged home (n = 4).

CONCLUSIONS AND RELEVANCE: The initial 12 US cases of CVST with thrombocytopenia after Ad26.COV2.S vaccination represent serious events. This case series may inform clinical guidance as Ad26.COV2.S vaccination resumes in the US as well as investigations into the potential relationship between Ad26.COV2.S vaccine and CVST with thrombocytopenia.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. See I, Su JR, Lale A, et al. US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021. JAMA. 2021. PMID: 33929487. doi:10.1001/jama.2021.7517

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。